Cantargia Zukünftiges Wachstum

Future Kriterienprüfungen 2/6

Cantargia wird ein Gewinn- und Umsatzwachstum von 30.6% bzw. 52.2% pro Jahr prognostiziert, während der Gewinn pro Aktie sinken soll.

Wichtige Informationen

30.6%

Wachstumsrate der Gewinne

-14.4%

EPS-Wachstumsrate

Biotechs Gewinnwachstum	39.6%
Wachstumsrate der Einnahmen	52.2%
Zukünftige Eigenkapitalrendite	n/a
Analystenabdeckung	Low
Zuletzt aktualisiert	22 May 2024

Jüngste Aktualisierungen zum künftigen Wachstum

Recent updates

An Intrinsic Calculation For Cantargia AB (publ) (STO:CANTA) Suggests It's 47% Undervalued

May 31

Here's Why We're Not Too Worried About Cantargia's (STO:CANTA) Cash Burn Situation

May 02

Is Cantargia (STO:CANTA) In A Good Position To Invest In Growth?

Jan 10

We Think Cantargia (STO:CANTA) Can Easily Afford To Drive Business Growth

Sep 20

Gewinn- und Umsatzwachstumsprognosen

OM:CANTA - Zukünftige Analystenschätzungen und Finanzdaten der Vergangenheit (SEK Millions)
Datum	Umsatz	Gewinne	Freier Cashflow	Bargeld aus operativen Tätigkeiten	Durchschn. Anz. Analysten
12/31/2026	N/A	-155	N/A	-178	1
12/31/2025	578	-99	N/A	351	1
12/31/2024	N/A	-294	N/A	-226	2
3/31/2024	N/A	-241	-267	-267	N/A
12/31/2023	N/A	-280	-287	-287	N/A
9/30/2023	N/A	-299	-299	-292	N/A
6/30/2023	N/A	-293	-295	-287	N/A
3/31/2023	N/A	-330	-320	-313	N/A
12/31/2022	N/A	-372	-366	-359	N/A
9/30/2022	N/A	-385	-387	-387	N/A
6/30/2022	N/A	-419	-419	-419	N/A
3/31/2022	N/A	-411	-406	-406	N/A
12/31/2021	N/A	-367	-347	-346	N/A
9/30/2021	N/A	-319	-302	-301	N/A
6/30/2021	N/A	-255	-231	-230	N/A
3/31/2021	N/A	-206	-187	-186	N/A
12/31/2020	N/A	-173	-165	-156	N/A
9/30/2020	N/A	-153	-165	-149	N/A
6/30/2020	N/A	-139	-151	-135	N/A
3/31/2020	N/A	-127	-144	-129	N/A
12/31/2019	N/A	-111	-118	-111	N/A
9/30/2019	N/A	-102	-97	-97	N/A
6/30/2019	N/A	-98	-92	-92	N/A
3/31/2019	N/A	-101	-88	-88	N/A
12/31/2018	N/A	-91	-105	-105	N/A
9/30/2018	N/A	-78	-72	-72	N/A
6/30/2018	N/A	-68	-65	-65	N/A
3/31/2018	N/A	-56	-54	-54	N/A
12/31/2017	N/A	-60	N/A	-41	N/A
9/30/2017	N/A	-65	N/A	-69	N/A
6/30/2017	N/A	-66	N/A	-64	N/A
3/31/2017	N/A	-58	N/A	-54	N/A
12/31/2016	N/A	-47	N/A	-42	N/A
9/30/2016	N/A	-34	N/A	-26	N/A
6/30/2016	N/A	-24	N/A	-21	N/A
3/31/2016	N/A	-22	N/A	-19	N/A
12/31/2015	N/A	-17	N/A	-30	N/A
9/30/2015	N/A	-15	N/A	-35	N/A
6/30/2015	N/A	-14	N/A	-13	N/A
3/31/2015	N/A	-10	N/A	-10	N/A
12/31/2014	N/A	-8	N/A	7	N/A

Analystenprognosen zum zukünftigen Wachstum

Einkommen vs. Sparrate: CANTA wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.

Ertrag vs. Markt: CANTA wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.

Hohe Wachstumserträge: CANTA wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.

Einnahmen vs. Markt: CANTADie Einnahmen des Unternehmens (52.2% pro Jahr) werden voraussichtlich schneller wachsen als der Markt Swedish (1.8% pro Jahr).

Hohe Wachstumseinnahmen: CANTADie Einnahmen des Unternehmens (52.2% pro Jahr) werden voraussichtlich schneller wachsen als 20% pro Jahr.

Wachstumsprognosen für den Gewinn je Aktie

Künftige Eigenkapitalrendite

Künftige Eigenkapitalrendite: Unzureichende Daten, um festzustellen, ob die Eigenkapitalrendite von CANTA in 3 Jahren voraussichtlich hoch sein wird

Cantargia Zukünftiges Wachstum

Future Kriterienprüfungen 2/6

Wichtige Informationen

Jüngste Aktualisierungen zum künftigen Wachstum

Forecast to breakeven in 2026

Price target decreased by 7.3% to kr12.67

Forecast to breakeven in 2026

No longer forecast to breakeven

Price target decreased to kr22.00

Forecast breakeven date pushed back to 2024

Recent updates

Cantargia AB (Publ) Reports Further Progress in Ongoing Phase 1 Clinical Trial with CAN10

Cantargia AB (Publ) Announces Appointment of Ton Berkien as Chief Business Officer, Effective October 1, 2024

Insufficient new directors

Cantargia Presents New Positive Clinical Data on Nadunolimab Counteracting Chemotherapy Induced Neuropathy

Forecast to breakeven in 2026

New major risk - Revenue and earnings growth

We're A Little Worried About Cantargia's (STO:CANTA) Cash Burn Rate

Cantargia Publishes New Data on the Can10 Antibody, Detailing Its Interaction with IL1RAP and Functional Inhibition

Cantargia AB (publ) Publishes Preclinical Data on the Potential of CAN10 in Systemic Sclerosis in A Leading Scientific Journal

New minor risk - Share price stability

Cantargia Publishes Data Highlighting the Potential of CAN10 in Atherosclerosis

Cantargia AB (publ) Reports Progress Towards Start of DOT-Sponsored Clinical Trial of Nadunolimab in Leukemia

Cantargia Reports New Data Highlighting Potential of CAN10 Antibody, Currently in Phase I Clinical Development, as Therapy in Systemic Sclerosis

Cantargia Reports New Preclinical Data on Antitumor Effects of nadunolimab in Pancreatic Cancer

Price target decreased by 7.3% to kr12.67

Forecast to breakeven in 2026

New major risk - Financial position

Cantargia AB (publ) to Report Fiscal Year 2024 Results on Feb 21, 2025

Cantargia Reports US Regulatory Approval to Start Pancreatic Cancer Phase IIB Trial with Nadunolimab

Cantargia Reports New Data Reinforcing Nadunolimab as Cancer Combination Therapy

Chief Executive Officer recently bought kr104k worth of stock

Cantargia Reports Phase I Clinical Progress in the CAN10 Project

Cantargia Reports New Preclinical Data Confirming the Potential of Nadunolimab and Can10

Chief Executive Officer recently bought kr103k worth of stock

New major risk - Revenue and earnings growth

New major risk - Financial position

Cantargia AB (publ) to Report Q2, 2024 Results on Aug 28, 2024

Cantargia AB (publ), Annual General Meeting, May 23, 2024

New minor risk - Shareholder dilution

Cantargia Presents New Clinical Data Further Supporting Nadunolimab's Antitumor Activity and A Key Role of Its Target IL1RAP in Pancreatic Cancer

Cantargia Reports New Preclinical Data on nadunolimab Potential to Enhance Anti-Tumor Effect of Immunotherapy Presented at CRI-ENCI-AACR

Cantargia AB (publ) Announces New Nadunolimab Clinical Trial in Leukemia Financed by External US Grant

Cantargia AB (publ)Expands Clinical Pipeline and Starts Treatment in Second Program, CAN10, for Autoimmune Diseases

No longer forecast to breakeven

New major risk - Financial position

Cantargia AB (publ) to Report Q1, 2024 Results on May 21, 2024

Cantargia AB (publ) Receives Regulatory Approval to Start Phase I Clinical Trial for CAN10

New minor risk - Share price stability

Is Cantargia (STO:CANTA) In A Good Position To Deliver On Growth Plans?

Cantargia Publishes ASCO 2023 Poster on Promising Nadunolimab Efficacy in Non-Small Cell Lung Cancer

Cantargia AB (publ) Promotes David Liberg to Chief Scientific Officer

Cantargia Extends Development of Nadunolimab in Pancreatic Cancer with New Controlled Phase IIb Clinical Trial Following Strong Phase IIb Efficacy Results

We Think Cantargia (STO:CANTA) Can Afford To Drive Business Growth

Cantargia Appoints Patrik Renblad as Chief Financial Officer

Chief Executive Officer recently bought kr140k worth of stock

Cantargia AB (publ) Successfully Concludes Toxicity Study with Can10 Antibody Ahead of Phase I Clinical Trial Application

Cantargia AB (Publ) Announces Nomination Committee Appointments

Is Cantargia (STO:CANTA) In A Good Position To Invest In Growth?

Price target decreased to kr22.00

Cantargia's CAN10 Demonstrates Positive Activity in Systemic Sclerosis Models in New Data Presented At ACR Convergence 2022

Cantargia AB (Publ) Presents New Data At SITC 2022 Supporting Nadunolimab's Promising Antitumor Clinical Efficacy

Cantargia Reaches Recruitment Milestone and Focuses Nadunolimab Development on Upcoming Randomized Studies

Cantargia AB (publ) to Report Q2, 2023 Results on Aug 22, 2023

Cantargia Reports First Non-Squamous NSCLC Patient Treated with Nadunolimab, Keytruda® and Chemotherapy

Cantargia Reports Preclinical Data Demonstrating Unique Treatment Effects of nadunolimab on Pancreatic Cancer Stromal Cells

Cantargia AB (Publ) Publishes Preclinical Data on Strong Anti-Tumor Efficacy of Nadunolimab in Combination with Chemotherapy

Cantargia Reports New Positive Preclinical Efficacy Data for CAN10 Supporting Development in Myocarditis

Cantargia Receives USPTO Notice of Allowance for Composition of Matter Patent on Antibody CAN10

Cantargia AB (Publ) Announces Executive Changes

An Intrinsic Calculation For Cantargia AB (publ) (STO:CANTA) Suggests It's 47% Undervalued

Cantargia Announces ASCO 2022 Presentation Strengthens Positive Phase IIa interim results for nadunolimab in NSCLC

Cantargia AB (publ) Presents Clinical Interim Results At ASCO 2022 Highlighting the Potential of Nadunolimab in Combination with Checkpoint Inhibitor

Cantargia AB (publ) Reports Positive Preclinical Effects in Atherosclerosis Demonstrating Potential of Can10 in Cardiovascular Disease

Forecast breakeven date pushed back to 2024

Here's Why We're Not Too Worried About Cantargia's (STO:CANTA) Cash Burn Situation

Price target decreased to kr42.00

Forecast breakeven date pushed back to 2024

Insider recently bought kr88k worth of stock

Cantargia Reports Positive Preclinical Efficacy Data for CAN10 Demonstrating Anti-Fibrotic and Anti-Inflammatory Effects in Systemic Sclerosis